Recruiting

Observational Study

Sponsor:

University Health Network, Toronto

Code:

NCT03569826

Conditions

Primary Bilary Cirrhosis (PBC)

Autoimmune Hepatitis

Overlap Syndrome

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Observational; no intervention

Study Details

Brief summary:

CaNAL is a longitudinal observational cohort study of patients diagnosed with Primary Biliary Cholangitis (PBC), Autoimmune Hepatitis (AIH), or overlap syndrome. This study creates a nationwide registry and network focusing on high quality long-term follow-up of individual patient data from major Canadian centers.

Primary Biliary Cholangitis (PBC) and Autoimmune Hepatitis (AIH) are rare and slowly progressive liver diseases associated with development of cirrhosis, liver cancer (HCC) and liver failure requiring liver transplantation or leading to premature death. The rarity and slowly progressive nature of these autoimmune liver diseases make them difficult to study and only a large scale approach combining patient data from multiple centers across Canada will allow new insights. The primary aim of the Canadian Network for Autoimmune Liver Disease is to build a Canadian registry of patients with PBC, AIH, and overlap syndrome. We capture patient characteristics, laboratory assessments and natural history, patient-reported outcomes including quality of life measures and environmental exposures, response to treatment, and pre- and post-transplant outcomes. We will then identify risk factors associated with critical outcomes for the patient, including response to treatment, progression to transplant, risk of liver cancer, and recurrent disease after transplant. We can identify biomarkers (biochemical indicators of progression of disease) to help diagnose autoimmune liver disease at its earliest stages, ensuring timely treatment and preventing disease progression. CaNAL will provide a better understanding of autoimmune liver diseases, biomarkers predictive of disease progression or non-response to therapy as well as better knowledge of the etiology and pathogenesis. CaNAL will also help to serve as a platform for conducting clinical trials or targeted lab-studies to answer important questions that are unlikely to be evaluated by the pharmaceutical industry.

Conditions

Primary Bilary Cirrhosis (PBC)

Autoimmune Hepatitis

Overlap Syndrome

Study ID

NCT03569826

Start date

Feb 7, 2018

Status verified date

Jun, 2021

Completion date

Dec, 2028

Anticipated

Primary completion date

Dec, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Diagnosis of Primary Biliary Cholangitis and/or Autoimmune Hepatitis

Exclusion Criteria:

  • Less than 18 years of age

Study Design

Enrollment

2500 participants

Anticipated

Interventions and Outcome Measures

Arms

Observational

There is no intervention being administered. This registry only observes patients through their regular standard of care visits.

Interventions

Observational; no intervention

Observational; no intervention

Primary outcome measure

  • Liver transplant-free survival over time [ Time Frame: Up to 6 years or time of death/liver transplant ]

Central Contacts and Locations

Central contacts

Locations

University of Alberta Hospital

Recruiting

Edmonton, Alberta, Canada, T6G 2B7

Contacts

Principal Investigator:

Andrew Mason, MD

London Health Sciences Centre - University Hospital

Recruiting

London, Ontario, Canada, N6A 5A5

Contacts

Principal Investigator:

Karim Qumosani, MD

The Ottawa Hospital

Recruiting

Ottawa, Ontario, Canada, K1H 8L6

Contacts

Miriam Muir

mmuir@toh.ca

Principal Investigator:

Angela Cheung, MD

Toronto General Hospital

Recruiting

Toronto, Ontario, Canada, M5G 2C4

Contacts

Principal Investigator:

Bettina Hansen, PhD

Centre hospitalier de l'Université de Montréal

Recruiting

Montréal, Quebec, Canada, H2X 0A9

Contacts

Principal Investigator:

Catherine Vincent, MD

Université de Sherbrooke

Recruiting

Sherbrooke, Quebec, Canada, J1G2E8

Contacts

Principal Investigator:

Dusanka Grbic, MD

Royal University Hospital

Recruiting

Saskatoon, Saskatchewan, Canada, S7N 0W8

Contacts

Principal Investigator:

Lawrence Worobetz, MD

More Information

Sponsor

University Health Network, Toronto

Last update posted

Jun 7, 2021

Last verified

Jun, 2021

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University Health Network, Toronto on 2021-06-07.